303.495.7583 info@intivabiopharma.com
teams Director

Lindy Snider

Founder/CEO, Lindy Skin

  • Founder, OnoCosmeteics
  • Board Affiliations: Cancer Forward, PSPCA, Snider Foundation and more
  • B.A. from Ithaca University and University of Pennsylvania
teams Advisory board member

Kevin McGovern

Chairman/CEO McGovern Capital & The Water Initiative

  • Founder, So Be Beverages
  • Board Affiliations: National Board of the Smithsonian, Silver Shield Foundation and more
  • BA from Cornell University, J.D. from St John’s University
teams Consultant

Joseph Morgan MD

25 years in pharmaceutical industry drug safety and clinical research

  • First Pennsylvania Diplomat of the American Academy of Cannabinoid Medicine
  • Guest Scientist in at Wm Patterson University, w/ Professor Emmanuel Onaivi
  • MD from Hahnemann/ Drexel University, Philadelphia
teams Consultant

Paul Wilkenson, Ph.D.

Assistant Professor of Pharmacy at the University of Connecticut and Auburn University

  • Pharmaceutical development manager including positions with J and J Pharmaceutical, Merck, Sharp and Dohme Research Laboratories, and RP Scherer
  • BS in Pharmacy from the University of Connecticut, MS in Pharmacy and his Ph.D. in Pharmaceutical Chemistry from the University of Michigan
teams Consultant

Linda Klumpers Ph.D.

Project leader at the CHDR Centre for Human Drug Research and Leiden University Medical Center

  • Published nine papers in international scientific journals, including the British Journal of Clinical Pharmacology and NeuroImage
  • Since 2010 she has been a recurring lecturer at the International Cannabis Masterclass
  • PH.D. in Clinical Pharmacology from the Leiden University Medical Center. MHBO Business Management from the NOCI, Woerden and M.Sc. in Medical Biology - Cognitive Neurosciences and Neurobiology, from the University of Amsterdam
teams Consultant

Lawrence C. Trost Ph.D. DABT

Board-Certified Toxicologist, a Non-clinical Pharmacokineticist and an expert in animal rule based drug development

  • Positions as: Director, Senior Director and Executive Director, Toxicology and Pharmacokinetics at Chimerix, Inc
  • Lead of a Brincidofovir project team for an FDA indication for treatment of smallpox where he conceived and executed smallpox development plans
  • B.S. Chemistry and M.S. in Pharmacology from the University of Minnesota, Ph.D. in Toxicology from the University of North Carolina
teams Director, Investor Relations

Mark Lubchenco

Director, Investor Relations, Intiva BioPharma Inc

  • President, Managing Partner, Cody Management Ltd
  • Vice President, FS Wealth Advisors
  • B.A. from University of Colorado, Boulder